Targeting the immune system to improve ventilatory function in muscular dystrophy.
Skeletal muscle is a unique tissue whose function is dependent in great part on its ultrastructure. Repeated intense muscular contractions, especially those resulting in muscle lengthening, can lead to alterations in muscle structure (i.e., muscle damage) and subsequent decline in contractile force. The damage-induced decline in contractile force can have a significant impact on exercise performance during an athletic performance. In some disease conditions such as Duchenne muscular dystrophy (DMD), the muscles are more vulnerable to contraction-induced damage than normal muscle. In the case of the respiratory muscles, for example, the diaphragm, the consequences of muscle weakness secondary to damage are profound in that respiratory failure leading to premature death often ensues. In normal skeletal muscle, damage is followed by an inflammatory response involving multiple cell types that subsides after several days. This transient inflammatory response is a normal homeostatic reaction to muscle damage. In contrast, a persistent inflammatory response is observed in dystrophic skeletal muscle that leads to an altered extracellular environment, including an increased presence of inflammatory cells (e.g., macrophages) and elevated levels of various inflammatory cytokines (e.g., TNF-alpha, TGF-beta). The signals that lead to successful muscle repair in healthy muscle may promote muscle wasting and fibrosis in dystrophic muscle. Preliminary data indicate that immunosuppression in dystrophic (mdx) mice has beneficial effects on some indices of muscle dysfunction, thereby indicating that targeted immunosuppression may offer some promise in delaying the pathological progression of this insidious muscular disease.
Gosselin
Luc E
LE
Exercise and Nutrition Sciences, University at Buffalo, State University of New York, Buffalo, NY 14214, USA. gosselin@acsu.buffalo.edu
McCormick
Kathleen M
KM
D000818:Animals; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D003094:Collagen / Q000096:biosynthesis; D003964:Diaphragm / Q000503:physiopathology*; D004195:Disease Models, Animal; D006801:Humans; D007249:Inflammation / Q000503:physiopathology; D051379:Mice; D008810:Mice, Inbred C57BL; D009136:Muscular Dystrophies / Q000188:drug therapy / Q000276:immunology / Q000503:physiopathology*; D011239:Prednisolone / Q000627:therapeutic use; D012129:Respiratory Function Tests; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors / Q000378:metabolism
D000893:Anti-Inflammatory Agents; D014409:Tumor Necrosis Factor-alpha; D003094:Collagen; D011239:Prednisolone